A Study On The Return Of Chinese Stocks

In the early domestic market,the listing standards were relatively high.In order to seek better development opportunities,domestic companies have listed overseas.However,since 2011,China's stock companies have encountered collective short selling.The stock price continued to be sluggish,and the refinancing of enterprises was difficult.At the same time,the domestic market was booming.In 2015,Stormwind successfully returned,and its market value soared 34 times.The huge domestic valuation has triggered a wave of privatization of the Chinese stocks.At this stage,the state has formulated a series of policies to support and encourage the return of high-quality stocks.It is foreseeable that in the near future,it will once again trigger a wave of returning stocks.In this context,the study of the way in which the stocks are returned is not only conducive to promoting the development of the company,but also to promote the progress of China's capital market.Taking WuXi Pharma Tech as an example,this paper studies its regression process,regression motivation,regression method and regression results.WuXi Pharma Tech's return process is mainly divided into four steps: splitting the whole medicine listed in the new three board,WuXi Pharma Tech's privatization delisting,splitting the Pharmacy Biological Port IPO,and WuXi Pharma Tech's main A-share IPO.The motivation for WuXi Pharma Tech's choice to return includes two aspects: On the one hand,WuXi Pharma Tech's market value is underestimated.Compared with domestic companies of the same level,the listed companies in the US have a market value that is several times different.The huge domestic valuation attracts the return of China Stocks.On the other hand,in the case that the US stock market is in a position to deviate from WuXi Pharma Tech's own development strategy,the company has to choose to return if it wants to expand its business and make strategic adjustments.In the choice of the return method,WuXi Pharma Tech's innovative demolition was returned to the three,and finally the WuXi Pharma Tech main body was listed on the A-share IPO.The reasons for WuXi Pharma Tech's choice of dismantling into three include three aspects: First,some parts of the company did not meet the A-share listing criteria,and the overall listing is more difficult.Therefore,the spin-off of the company will benefit the company's overall return.Secondly,WuXi Pharma Tech's various businesses are very independent.After the spin-off,it can meet the needs of different business developments of WuXi Pharma Tech.The last split into three occupy three different capital markets,which can maximize the company's market value.The return of WuXi Pharma Tech's main body by IPO is based on the current backdoor regression and is supported by the regulatory authorities due to policy restrictions and IPO methods.After the analysis of the results of WuXi Pharma Tech's return,it was found that the company's revenue,net profit,stock price and market value increased significantly after the reunification.Based on the analysis of the above content,relevant suggestions are proposed.The Chinese stock company should choose the appropriate return timing and return method;the regulatory body should improve the multi-level capital market system and promote the diversification of the stock return method,so as to attract more high-quality Chinese stocks to return,in addition to the return The company must strengthen supervision.